Home > > > > Report Detail

China Human Vaccine Industry Report, 2018-2022

Publisher Name :
Date: 23-Oct-2018
No. of pages: 155

As the world’s largest producer of human vaccines, China has established a full-life-cycleregulatory system covering vaccine R&D, production, distribution, and vaccination.

The lot release volume of human vaccines has remained at around 650 million doses over the past three years. China Food and Drug Administration (CFDA) approved the launch of 9-valent human papillomavirus vaccine (saccharomyces cerevisiae) and oral 5-valent reassortant rotavirus attenuated live vaccine (Vero cell) in the first half of 2018. The National Institutes for Food and Drug Control, Hubei Institute for Food and Drug Control, and Shanghai Institute for Food and Drug Control approved supply of 434.1 million doses (44 kinds of vaccines) to the market from January to September 2018.

With annual capacity of over one billion doses, more than forty vaccine manufacturers in China are capable of producing 63 kinds of vaccines for prevention of 34 sorts of infectious diseases. Among them, Chengdu Institute of Biological Products, Shanghai Institute of Biological Products, Lanzhou Institute of Biological Products, Wuhan Institute of Biological Products, Changchun Institute of Biological Products, Beijing Bio-Institute Biological Products, Changchun KEYGEN Biological Products, and Beijing Tiantan Biological Products (Beijing Tiantan Biological Products has no vaccine business after completion of asset restructuring in May 2017) under China National Biotech Group Co., Ltd. occupy half of the Chinese vaccine market. The subsidiaries under China National Biotech Group Co., Ltd. recorded lot release volume of 349.147 million doses in 2017 and 198.261 million doses in the first nine months of 2018, making up 53.1% and 45.7% of the country’s total amount, respectively.

In recent years, Chinese vaccine companies have spared no efforts in research and development to sharpen competitiveness. As yet, not a Chinese enterprise can produce HPV vaccines and 13-valent pneumonia vaccines, but local companies including Walvax Biotechnology and Shenzhen Kangtai Biological Products are developing such vaccines which are expected to be available soon.

With the implementation of two-child policy, the aging of population and the launch of new-type vaccines, China’s human vaccine industry will grow steadily in future, with the expected market size of RMB35.2 billion by 2022. Meanwhile, vaccine companies with richer capital and stronger R&D strength will give play to technological superiorities and scale effect, and raise their market share through capital operation and other means. In this sense, China’s vaccine industry tends to feature higher and higher concentration.

hina Human Vaccine Industry Report, 2018-2022 highlights the following:


  • China’s human vaccine industry (operating environment, status quo, market demand, distribution channels, market size, import and export, and competitive landscape);

  • Chinese human vaccine market segments (market demand, lot release volume and competitive landscape);

  • 22 human vaccine companies (operation, R&D and investment, development strategy, etc.) .

China Human Vaccine Industry Report, 2018-2022

Table of Contents

1. Overview of Vaccine Industry
1.1 Definition & Classification
1.2 Industry Chain

2. China Human Vaccine Industry
2.1 Operating Environment
2.1.1 International Market
2.1.2 Policy Environment
2.1.3 Biopharmaceutical Market
2.2 Status Quo
2.3 Market Demand
2.4 Circulation Channels
2.5 Market Size
2.6 Import & Export
2.6.1 Import
2.6.2 Export
2.6.3 Average Price
2.7 Competition Pattern

3. Human Vaccine Market Segments in China
3.1 Hepatitis B Vaccine
3.1.1 Demand
3.1.2 Lot Release Volume
3.1.3 Competition Pattern
3.2 Meningococcal Vaccine
3.2.1 Demand
3.2.2 Lot Release Volume
3.2.3 Competition Pattern
3.3 Hepatitis A Vaccine
3.3.1 Demand
3.3.2 Lot Release Volume
3.3.3 Competition Pattern
3.4 Influenza Vaccine
3.4.1 Demand
3.4.2 Lot Release Volume
3.4.3 Competition Pattern
3.5 Hib Vaccine
3.5.1 Demand
3.5.2 Lot Release Volume
3.5.3 Competition Pattern
3.6 Human Rabies Vaccine
3.6.1 Demand
3.6.2 Lot Release Volume
3.6.3 Competition Pattern
3.7 Varicella Vaccine
3.7.1 Demand
3.7.2 Lot Release Volume
3.7.3 Competition Pattern
3.8 Pneumococcal Vaccines
3.8.1 Demand
3.8.2 Lot Release Volume
3.8.3 Competition Pattern
3.9 DTP Vaccine
3.9.1 Demand
3.9.2 Lot Release Volume
3.9.3 Competition Pattern
3.10 Poliomyelitis Vaccine
3.10.1 Demand
3.10.2 Lot Release Volume
3.10.3 Competition Pattern
3.11 Hepatitis E Vaccine
3.11.1 Demand
3.11.2 Lot Release Volume
3.11.3 Competition Pattern

4. Major Human Vaccine Manufacturers in China
4.1 China National Biotech Group
4.1.1 Profile
4.1.2 National Vaccine and Serum Institute
4.1.3 Chengdu Institute of Biological Products Co., Ltd.
4.1.4 Shanghai Institute of Biological Products Co., Ltd.
4.1.5 Wuhan Institute of Biological Products Co., Ltd.
4.1.6 Lanzhou Institute of Biological Products Co., Ltd.
4.1.7 Changchun Institute of Biological Products Co., Ltd.
4.2 Beijing Tiantan Biological Products Co., Ltd.
4.2.1 Profile
4.2.2 Operation
4.2.3 Revenue Structure
4.2.4 Gross Margin
4.2.5 R&D
4.2.6 Vaccine Business
4.3 Hualan Biological Engineering Inc.
4.3.1 Profile
4.3.2 Operation
4.3.3 Revenue Structure
4.3.4 R&D
4.3.5 Vaccine Business
4.3.6 Development Strategy
4.4 Chongqing Zhifei Biological Products Co., Ltd.
4.4.1 Profile
4.4.2 Operation
4.4.3 Revenue Structure
4.4.4 Gross Margin
4.4.5 R&D
4.4.6 Development Dynamics
4.4.7 Development Strategy
4.5 Walvax Biotechnology Co, Ltd.
4.5.1 Profile
4.5.2 Operation
4.5.3 Revenue Structure
4.5.4 Gross Margin
4.5.5 R&D
4.5.6 Vaccine Business
4.5.7 Development Trend
4.6 Liaoning Cheng Da Co., Ltd.
4.6.1 Profile
4.6.2 Operation
4.6.3 Revenue Structure
4.6.4 Gross Margin
4.6.5 Major Customers
4.6.6 R&D
4.6.7 Development Strategy
4.7 Shenzhen Kangtai Biological Products Co., Ltd.
4.7.1 Profile
4.7.2 Operation
4.7.3 Revenue Structure
4.7.4 Gross Margin
4.7.5 R&D
4.7.6 Development Strategy
4.8 Changsheng Bio-Technology Co., Ltd.
4.8.1 Profile
4.8.2 Operation
4.8.3 Revenue Structure
4.8.4 R&D
4.8.5 Development Dynamics
4.9 Olymvax Biopharmaceuticals Inc.
4.9.1 Profile
4.9.2 Operation
4.9.3 R&D
4.10 Sinovac Biotech Ltd.
4.10.1 Profile
4.10.2 Operation
4.10.3 Revenue Structure
4.10.4 Sinovac Biotech (Beijing)
4.11 Changchun BCHT Biotechnology Co. Ltd.
4.11.1 Profile
4.11.2 Operation
4.11.3 Development Dynamics
4.12 Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd.
4.12.1 Profile
4.12.2 Operation
4.13 Dalian Hissen Bio-Pharm Co., Ltd.
4.13.1 Profile
4.13.2 Vaccine Business
4.14 NCPC GeneTech Biotechnology Development Co., Ltd.
4.14.1 Profile
4.14.2 Operation
4.15 Dalian Aleph Biomedical Co., Ltd.
4.15.1 Profile
4.15.2 Vaccine Business
4.16 Beijing Minhai Biotechnology Co., Ltd.
4.16.1 Profile
4.16.2 Operation
4.17 Shenzhen Sanofi Pasteur Biological Products Co., Ltd.
4.17.1 Profile
4.17.2 Operation
4.18 Other Enterprises
4.18.1 Xiamen Innovax Biotech Co., Ltd.
4.18.2 Convac Biotechnology Co., Ltd.
4.18.3 Chengdu Kanghua Biological Products Co.,Ltd.
4.18.4 Guangzhou Nuocheng Biological Products
4.18.5 CanSino Biologics Inc.

5 Summary and Forecast
5.1 Summary
5.2 Development Trends
5.2.1 Human Vaccine Industry is Increasingly Concentrated
5.2.2 Two-child Policy is in Favor of Human Vaccine Industry Growth
5.2.3 Faster Aging of Population Boosts Human Vaccine Industry
5.2.4 Human Papillomavirus (HPV) Vaccine Market is Promising
5.2.5 Homemade 13-valent Pneumococcal Conjugate Vaccine is Likely to be Launched
5.2.6 Local Companies Invest More Heavily in Research and Development of Vaccine Products Which are Becoming More Various

List of Charts
Classification of Vaccines
Vaccine Industry Chain
Global Human Vaccine Market Size, 2010-2017
Global Human Vaccine Market Size, 2017-2022E
Revenue of Major Global Vaccine Companies, 2013-2017
Main Mergers & Acquisitions in the Vaccine Industry Worldwide, 2005-2017
Related Policies in China Human Vaccine Industry, 2006-2017
Gross Industrial Output Value of China Biopharmaceutical Industry, 2008-2017
Gross Industrial Output Value of China Biopharmaceutical Industry, 2016-2022E
EPI Human Vaccine Varieties in China
Lot Release Volume of Human Vaccine in China, 2013-2018
Top10 Human Vaccines by Lot Release Volume in China, 2013-2018
Main Human Vaccine Varieties and Producers Granted Permit for Lot Release in China, Jan.-Sep. 2018
China Human Vaccine Market Size, 2010-2018
Import Volume and Value of Human Vaccine in China, 2010-2017
Export Volume and Value of Human Vaccine in China, 2010-2017
Average Unit Export/Import Price of Human Vaccine in China, 2010-2017
Lot Release Volume Breakdown of Human Vaccines in China by Nature of Enterprise, 2017
Lot Release Volume Breakdown of Human Vaccines in China by Nature of Enterprise, Jan.-Sep.2018
Human Vaccine Lot Release Volume of Major Vaccine Enterprises in China, 2014-2018
Lot Release Volume of Human Vaccines in China by Enterprise, 2017
Lot Release Volume of Human Vaccines in China by Enterprise, Jan.-Sep.2018
Vaccine Revenue of Major Human Vaccine Enterprises in China, 2013-2018
Hepatitis B Morbidity and Mortality in China, 2013-2017
Hepatitis B Morbidity and Mortality in China, Jan.-Sep.2018
Lot Release Volume of Hepatitis B Vaccine in China, 2013-2018
Lot Release Volume of Hepatitis B Vaccine in China by Dosage Form, 2013-2018
Lot Release Volume of Major Hepatitis B Vaccine Companies in China, 2013-2018
Share of Major Hepatitis B Vaccine Companies by Lot Release Volume in China, 2013-2018
Meningitis Morbidity and Mortality in China, 2013-2017
Meningitis Morbidity and Mortality in China, Jan.-Sep. 2018
Meningococcal Vaccines Lot Release Volume in China, 2013-2018
Meningococcal Vaccines Lot Release Volume in China by Type, 2013-2018
Lot Release Volume of Major Meningococcal Vaccines Companies in China, 2013-2018
Share of Major Meningococcal Vaccines Companies by Lot Release Volume in China, 2013-2018
Hepatitis A Morbidity and Mortality in China, 2013-2017
Hepatitis A Morbidity and Mortality in China, Jan.-Sep. 2018
Lot Release Volume of Hepatitis A Vaccine in China, 2013-2018
Lot Release Volume of Major Hepatitis A Vaccine Companies in China, 2013-2018
Share of Major Hepatitis A Vaccine Companies by Lot Release Volume in China, 2013-2018
Influenza Morbidity and Mortality in China, 2013-2017
Influenza Morbidity and Mortality in China, Jan.-Sep. 2018
H7N9 Influenza Morbidity and Mortality in China, 2013-2017
H7N9 Influenza Morbidity and Mortality in China, Jan.-Sep. 2018
Lot Release Volume of Influenza Vaccine in China, 2013-2018
Lot Release Volume of Major Influenza Vaccine Companies in China, 2013-2018
Share of Major Influenza Vaccine Companies by Lot Release Volume in China, 2013-2018
Lot Release Volume of Hib Vaccine in China, 2013-2018
Lot Release Volume of Major Hib Vaccine Companies in China, 2013-2018
Share of Major Hib Vaccine Companies by Lot Release Volume in China, 2013-2018
Rabies Morbidity and Mortality in China, 2013-2017
Rabies Morbidity and Mortality in China, Jan.-Sep. 2018
Lot Release Volume of Human Rabies Vaccine in China, 2013-2018
Lot Release Volume of Major Human Rabies Vaccine Companies in China, 2013-2018
Share of Major Human Rabies Vaccine Companies by Lot Release Volume in China, 2013-2018
Lot Release Volume of Varicella Vaccine in China, 2013-2018
Lot Release Volume of Major Varicella Vaccine Companies in China, 2013-2018
Share of Major Varicella Vaccine Companies by Lot Release Volume in China, 2013-2018
Lot Release Volume of Pneumococcal Vaccines in China, 2013-2018
Lot Release Volume of Major Pneumococcal Vaccines Companies in China, 2013-2018
Share of Major Pneumococcal Vaccine Companies by Lot Release Volume in China, 2013-2018
Pertussis Morbidity and Mortality in China, 2012-2017
Pertussis Morbidity and Mortality in China, Jan.-Sep. 2018
Neonatal Tetanus Morbidity and Mortality in China, 2012-2017
Neonatal Tetanus Morbidity and Mortality in China, Jan.-Sep. 2018
Lot Release Volume of DTP Vaccine in China, 2013-2018
Lot Release Volume of Major DTP Vaccine Companies in China, 2013-2018
Share of Major DTP Vaccine Companies by Lot Release Volume in China, 2013-2018
Poliomyelitis Morbidity and Mortality in China, 2013-2018
Lot Release Volume of Poliomyelitis Vaccine Companies in China, 2013-2018
Share of Major Poliomyelitis Vaccine Companies by Lot Release Volume in China, 2013-2018
Hepatitis E Morbidity and Mortality in China, 2012-2017
Hepatitis E Morbidity and Mortality in China, Jan.-Sep. 2018
Lot Release Volume of Hepatitis E Vaccine in China, 2013-2018
Lot Release Volume of Major Hepatitis E Vaccine Companies in China, 2013-2018
Specifications and Place of Origin of China National Biotech Group’s Main Vaccine Products  
Revenue and Net Income of Beijing Tiantan Biological Products, 2013-2018
Revenue Breakdown of Beijing Tiantan Biological Products by Product, 2013-2017
Revenue Structure of Beijing Tiantan Biological Products by Product, 2013-2017
Revenue Breakdown of Beijing Tiantan Biological Products by Region, 2013-2017
Revenue Structure of Beijing Tiantan Biological Products by Region, 2013-2017
Gross Margin of Beijing Tiantan Biological Products by Product, 2013-2017
R&D Costs and % of Total Revenue of Beijing Tiantan Biological Products, 2013-2018
R&D Costs and % of Total Revenue of Beijing Tiantan Biological Products, 2013-2017
Revenue and Net Income of Hualan Biological Engineering, 2013-2018
Revenue Breakdown of Hualan Biological Engineering by Sector, 2013-2018
Revenue Structure of Hualan Biological Engineering by Sector, 2013-2018
R&D Costs and % of Total Revenue of Hualan Biological Engineering, 2013-2018
Output & Sales Volume, Inventory of Hualan Biological Engineering, 2013-2017
Vaccine Revenue and Percentage of Hualan Biological Engineering, 2013-2018
Main Products Chongqing Zhifei Biological Products is Selling or Promoting according to Agreements, and Their Purposes
Revenue and Net Income of Chongqing Zhifei Biological Products, 2012-2018
Revenue Breakdown of Chongqing Zhifei Biological Products by Product, 2014-2017
Lot Release Volume Breakdown of Chongqing Zhifei Biological Products by Product, 2014-2018
Revenue Breakdown of Chongqing Zhifei Biological Products by Region, 2014-2017
Gross Margin of Chongqing Zhifei Biological Products by Product, 2013-2018
R&D Costs and % of Total Revenue of Chongqing Zhifei Biological Products, 2011-2018
Projects under Registration Process of Chongqing Zhifei Biological Products, as of 2018H1
Progress of Preclinical Projects of Chongqing Zhifei Biological Products by 2018H1
Revenue and Net Income of Walvax Biotechnology, 2013-2018
Revenue Breakdown of Walvax Biotechnology by Product, 2014-2017
Revenue Breakdown of Walvax Biotechnology by Region, 2014-2017
Gross Margin of Own Vaccine of Walvax Biotechnology, 2013-2017
R&D Costs and % of Total Revenue of Walvax Biotechnology, 2013-2018
Progress of Walvax Biotechnology’s Projects with Raised Fund, as of 2018 H1
Progress of Products under Registration Declaration of Walvax Biotechnology, as of 2018H1
Output & Sales Volume, Inventory of Walvax Biotechnology, 2014-2017
Lot Release Volume of Walvax Biotechnology, 2014-2018
Revenue and Net Income of Liaoning Chengda, 2013-2018
Revenue Breakdown of Liaoning Chengda by Product, 2013-2018
Revenue Structure of Liaoning Chengda by Product, 2013-2018
Gross Margin of Liaoning Chengda, 2013-2018
Liaoning Chengda’s Revenue from Top5 Customers and % of Total Revenue, 2015-2017
R&D Costs and % of Total Revenue of Liaoning Chengda, 2014-2017
Main Products and Their Purposes of Shenzhen Kangtai Biological Products  
Capacity, Output & Sales Volume of Shenzhen Kangtai Biological Products, 2013-2017
Revenue and Net Income of Shenzhen Kangtai Biological Products, 2013-2018
Revenue Breakdown of Shenzhen Kangtai Biological Products by Product, 2015-2018
Lot Release Volume and Percentage of Shenzhen Kangtai Biological Products, 2015-2018
Revenue Breakdown of Shenzhen Kangtai Biological Products by Region, 2015-2018
Gross Margin of Shenzhen Kangtai Biological Products, 2013-2017
R&D Costs and % of Total Revenue of Shenzhen Kangtai Biological Products, 2013-2018
Progress of Research Projects of Shenzhen Kangtai Biological Products, as of 2018H1
Major Non-equity Investments by Shenzhen Kangtai Biological Products, as of 2018H1
Revenue and Net Income of Changsheng Bio-technology, 2014-2017
Revenue Breakdown of Changsheng Bio-technology by Product, 2014-2017
Revenue Structure of Changsheng Bio-technology by Product, 2014-2017
Output & Sales Volume, Inventory of Changsheng Bio-technology, 2014-2017
Progress of Ongoing Projects of Changsheng Bio-technology as of the end of 2017
R&D Costs and % of Total Revenue of Changsheng Bio-technology, 2014-2017
Development Course of Olymvax Biopharmaceuticals
Revenue and Net Income of Olymvax Biopharmaceuticals, 2014-2018
Research Progress of Products Developed by Olymvax Biopharmaceuticals
Main Products of Sinovac Biotech
Revenue and Net Income of Sinovac Biotech, 2013-2017
Revenue Breakdown of Sinovac Biotech by Product, 2013-2017
Equity Structured of Sinovac Biotech
Financial Indices of Sinovac Biotech, 2015-2017
Financial Indices of Changchun BCHT Biotechnology, 2014-2018
Equity Structure of Zhejiang Tianyuan Bio-Pharmaceutical
Revenue and Net Income of Zhejiang Tianyuan Bio-Pharmaceutical, 2013-2016
Financial Indices of NCPC GeneTech Biotechnology Development, 2014-2018
Development Goals of Dalian Aleph Biomedical
Financial Indices of Beijing Minhai Biotechnology, 2015-2018
Development Course of Xiamen Innovax Biotech
Main Partners of CanSino Biologics
Products Being Researched by CanSino Biologics
China’s Vaccine Market Size, 2017-2022E
Number of Newborns in China, 2015-2022E
China’s Population Aged over 60 and % of Total Population, 2009-2017
Global Incidence of Cervical Cancer
HPV Vaccine Products Worldwide
Global HPV Vaccine Market Size, 2006-2015
Lot Release Volume of HPV Vaccine in China by Enterprise, Jan-Sept 2018
Major HPV Vaccine Developers in China and Their Progress
Major 13-valent Pneumococcal Conjugate Vaccine Developers in China and Their Progress
R&D Investment of Major Vaccine Companies in China, 2013-2018
Main Vaccine Products Being Researched by Companies in China and Their Progress 

  • Global BCG Vaccine Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 96
    According to our LPI (LP Information) latest study, the global BCG Vaccine market size was valued at US$ 365.6 million in 2023. With growing demand in downstream market, the BCG Vaccine is forecast to a readjusted size of US$ 542.8 million by 2030 with a CAGR of 5.8% during review period. The research report highlights the growth potential of the global BCG Vaccine market. BCG Vaccine are expected to show stable growth in the future market. However, product differentiation, reducing cost......
  • Global Peptide Cancer Vaccine Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 115
    According to our LPI (LP Information) latest study, the global Peptide Cancer Vaccine market size was valued at US$ 535 million in 2023. With growing demand in downstream market, the Peptide Cancer Vaccine is forecast to a readjusted size of US$ 1978.2 million by 2030 with a CAGR of 20.5% during review period. The research report highlights the growth potential of the global Peptide Cancer Vaccine market. Peptide Cancer Vaccine are expected to show stable growth in the future market. How......
  • Global Cancer Vaccine Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 26-Dec-2023        Price: US 3380 Onwards        Pages: 101
    Market Overview of Global Cancer Vaccine market: According to our latest research, the global Cancer Vaccine market looks promising in the next 5 years. As of 2022, the global Cancer Vaccine market was estimated at USD 7198.2 million, and it's anticipated to reach USD 33936.62 million in 2028, with a CAGR of 29.49% during the forecast years. A cancer vaccine is a type of immunotherapy that boost the body's natural defenses by stimulating the immune system to recognize and cur......
  • Global Lung Cancer Vaccines Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 12-Dec-2023        Price: US 3380 Onwards        Pages: 102
    Market Overview of Global Lung Cancer Vaccines market: According to our latest research, the global Lung Cancer Vaccines market looks promising in the next 5 years. As of 2022, the global Lung Cancer Vaccines market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. Lung Cancer Vaccines,A cancer vaccine for lung cance This report covers a research time span from 2018 to 2028, and ......
  • Global Cancer Vaccines Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 07-Dec-2023        Price: US 3380 Onwards        Pages: 105
    Market Overview of Global Cancer Vaccines market: According to our latest research, the global Cancer Vaccines market looks promising in the next 5 years. As of 2022, the global Cancer Vaccines market was estimated at USD 5773.14 million, and it's anticipated to reach USD 15406.41 million in 2028, with a CAGR of 17.77% during the forecast years. This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of the global Cancer Vacci......
  • Global Dendritic Cell Cancer Vaccine Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 16-Nov-2023        Price: US 3380 Onwards        Pages: 110
    Market Overview of Global Dendritic Cell Cancer Vaccine market: According to our latest research, the global Dendritic Cell Cancer Vaccine market looks promising in the next 5 years. As of 2022, the global Dendritic Cell Cancer Vaccine market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. Dendritic cells (DC) are one of the major antigen presenting cells found in lymphoid organs. The main fu......
  • Global BCG Vaccine Market Research Report 2023, Forecast to 2028
    Published: 14-Nov-2023        Price: US 2680 Onwards        Pages: 135
    BCG Vaccine is not given as part of the routine NHS vaccination schedule. It's given on the NHS only when a child or adult is thought to have an increased risk of coming into contact with TB. Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their goals while taking advantage o......
  • Global BCG Vaccine Professional Survey Report 2023, Forecast to 2028
    Published: 14-Nov-2023        Price: US 3280 Onwards        Pages: 105
    BCG Vaccine is not given as part of the routine NHS vaccination schedule. It's given on the NHS only when a child or adult is thought to have an increased risk of coming into contact with TB. Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their goals while taking advantage o......
  • Infectious Vaccine Collaboration and Licensing Deals 2016-2023
    Published: 01-Nov-2023        Price: US 3995 Onwards        Pages: 300
    Infectious Vaccine Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the infectious vaccine deals entered into by the worlds leading biopharma companies. Fully revised and updated, the report provides details of infectious vaccine deals from 2016 to 2023. The report provides a detailed understanding and analysis of how and why companies enter infectious vaccine deals. These deals tend to be multicomponent, starting with......
    • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs